Suppr超能文献

恶性胸膜间皮瘤渗出液中的 microRNA 特征。

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.

机构信息

Institute for Respiratory Health and Centre for Respiratory Health, School of Biomedical Sciences, University of Western Australia, Nedlands, WA 6009, Australia.

Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, University of Western Australia and Harry Perkins Institute of Medical Research, Nedlands, WA 6009, Australia.

出版信息

Dis Markers. 2019 Jul 31;2019:8628612. doi: 10.1155/2019/8628612. eCollection 2019.

Abstract

Malignant pleural mesothelioma (MPM) is an incurable cancer of the pleura that can be difficult to diagnose. Biomarkers for an easier and/or earlier diagnosis are needed. Approximately 90% of MPM patients develop a pleural effusion (PE). PEs are ideal sources of biomarkers as the fluid would almost always require drainage for diagnostic and/or therapeutic reasons. However, differentiating MPM PE from PE caused by other diseases can be challenging. MicroRNAs are popular biomarkers given their stable expression in tissue and fluid. MicroRNAs have been analysed in PE cytology samples for the diagnosis of MPM but have not been measured in frozen/fresh PE. We hypothesise that microRNAs expressed in PE are biomarkers for MPM. TaqMan OpenArray was used to analyse over 700 microRNAs in PE cells and supernatants from 26 MPMs and 21 other PE-causing diseases. In PE cells, combining miR-143, miR-210, and miR-200c could differentiate MPM with an area under the curve (AUC) of 0.92. The three-microRNA signature could also discriminate MPM from a further 40 adenocarcinomas with an AUC of 0.9887. These results suggest that the expression of miR-143, miR-210, and miR-200c in PE cells might provide a signature for diagnosing MPM.

摘要

恶性胸膜间皮瘤(MPM)是一种难以诊断的胸膜间皮恶性肿瘤。需要有更容易和/或更早诊断的生物标志物。大约 90%的 MPM 患者会出现胸腔积液(PE)。PE 是生物标志物的理想来源,因为由于诊断和/或治疗原因,几乎总是需要引流胸腔积液。然而,区分 MPM 性 PE 和由其他疾病引起的 PE 可能具有挑战性。由于 microRNA 在组织和液体中的稳定表达,它们是很受欢迎的生物标志物。已经在 PE 细胞学样本中分析了 microRNA 用于诊断 MPM,但尚未在冷冻/新鲜 PE 中进行测量。我们假设在 PE 中表达的 microRNA 是 MPM 的生物标志物。TaqMan OpenArray 用于分析 26 例 MPM 和 21 例其他引起 PE 的疾病的 PE 细胞和上清液中的 700 多个 microRNA。在 PE 细胞中,组合 miR-143、miR-210 和 miR-200c 可以区分 MPM,曲线下面积(AUC)为 0.92。这三个 microRNA 特征也可以将 MPM 与另外 40 个腺癌区分开来,AUC 为 0.9887。这些结果表明,PE 细胞中 miR-143、miR-210 和 miR-200c 的表达可能为诊断 MPM 提供特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d999/6701424/8c8f5d5d2111/DM2019-8628612.001.jpg

相似文献

1
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.
Dis Markers. 2019 Jul 31;2019:8628612. doi: 10.1155/2019/8628612. eCollection 2019.
2
miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cancer Cytopathol. 2017 Aug;125(8):635-643. doi: 10.1002/cncy.21869. Epub 2017 Apr 27.
4
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Lung Cancer. 2013 Dec;82(3):485-90. doi: 10.1016/j.lungcan.2013.09.017. Epub 2013 Oct 10.
5
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
J Thorac Oncol. 2017 Sep;12(9):1421-1433. doi: 10.1016/j.jtho.2017.05.024. Epub 2017 Jun 16.

引用本文的文献

1
Volatile organic compounds in exhaled human breath for the diagnosis of malignant pleural mesothelioma: a meta-analysis.
Front Oncol. 2025 May 28;15:1537767. doi: 10.3389/fonc.2025.1537767. eCollection 2025.
2
Optimal isolation of extracellular vesicles from pleural fluid and profiling of their microRNA cargo.
J Extracell Biol. 2023 Oct 16;2(10):e119. doi: 10.1002/jex2.119. eCollection 2023 Oct.
3
Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.
Curr Med Chem. 2025;32(11):2093-2114. doi: 10.2174/0109298673268206240405084558.
4
Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
J Clin Med. 2023 Nov 9;12(22):7006. doi: 10.3390/jcm12227006.
6
Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.
Eur Respir Rev. 2021 Nov 17;30(162). doi: 10.1183/16000617.0057-2021. Print 2021 Dec 31.
7
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.
J Clin Med. 2021 Mar 3;10(5):1034. doi: 10.3390/jcm10051034.
8
Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini-review.
Thorac Cancer. 2021 Jan;12(1):8-12. doi: 10.1111/1759-7714.13746. Epub 2020 Nov 22.
10
Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
Int J Mol Sci. 2020 Sep 1;21(17):6342. doi: 10.3390/ijms21176342.

本文引用的文献

1
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Cancers (Basel). 2018 Mar 14;10(3):72. doi: 10.3390/cancers10030072.
2
Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.
Oncotarget. 2017 Aug 24;8(44):78193-78207. doi: 10.18632/oncotarget.20409. eCollection 2017 Sep 29.
3
miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cancer Cytopathol. 2017 Aug;125(8):635-643. doi: 10.1002/cncy.21869. Epub 2017 Apr 27.
4
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016.
5
Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
Oncotarget. 2016 Dec 20;7(51):84851-84859. doi: 10.18632/oncotarget.12707.
6
New therapeutic strategies for malignant pleural mesothelioma.
Biochem Pharmacol. 2017 Jan 1;123:8-18. doi: 10.1016/j.bcp.2016.07.012. Epub 2016 Jul 16.
7
Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Ther Adv Respir Dis. 2016 Jun;10(3):275-88. doi: 10.1177/1753465816628800. Epub 2016 Feb 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验